Johnson & Johnson (JNJ) Stock Price, Quote & News

Company Profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 732 524 0400

Website: www.jnj.com

Address:

One Johnson & Johnson Plaza, New Brunswick, United States

TalkMarkets Jan. 1 at 3:00 PM

Johnson & Johnson Near Year High $JNJ Also $ABBV $BSX $HALO https://talkmarkets.com/content/stocks--equities/johnson--johnson-near-year-high?post=547778&userid=166882

0 · Reply

SueHarri Jan. 1 at 2:15 PM

$CVKD Cadrenal’s strategic pipeline build could reshape how investors see the company: https://finance.yahoo.com/news/cadrenals-quiet-expansion-play-starting-160000079.html $ASTS $NOW $JNJ $ASML

0 · Reply

LeeBeckwith675 Jan. 1 at 1:34 PM

$MA $XOM $JNJ $PLTR $NFLX I agree with this

0 · Reply

MoneyGroupLLC Jan. 1 at 12:04 AM

Enter: $JNJ Calls Strike Price: $210 Expiry Date: JAN 23 2026 Buy in Price: $3.45 - $3.47 Sell Price: $6.59 Profit : +90% (Turn every $1 into $1.90) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

Jamessmithy Dec. 31 at 11:17 PM

$JNJ $CL $LEU $PG $CRSP

0 · Reply

Night_Owl_Biotech Dec. 31 at 9:56 PM

Q4 2025 commercial-stage oncology focused bio share price changes. This is not investment advice. $NUVB (no surprise) was the best performing stock in this peer group during the quarter. $SNDX continues to be our top pick for a near-term M&A exit. We don't have a clue what will happen to the share price of any company (bio or otherwise) but we suspect $LEGN will continue to struggle until we get updated guidance from $JNJ (good or bad). J&J reported data from their combo therapy that considerably outperformed Carvykti in R/R MM. $ONC was profiled as a top M&A candidate but... For entertainment purposes only.

1 · Reply

N0Bounds Dec. 31 at 9:49 PM

SNSE is the Next big Retail Squeeze!! $JNJ $OCG $SES $UAMY $JOBY /

0 · Reply

N0Bounds Dec. 31 at 9:24 PM

$GEMI $LI $JNJ $UAMY $NDAQ bw

0 · Reply

DennisFrank550 Dec. 31 at 4:49 PM

$MA $XOM $JNJ $PLTR $NFLX I agree with this

0 · Reply

Investor203 Dec. 31 at 3:04 PM

$VNDA $720 million dollars market per year. They have the best results. If they get 20% of the market then it would be $140-$150 million/year. Stock should be $17-$19 to start with in 2-4 months. $JNJ will buy it soon

0 · Reply

Best Dividend Aristocrats For January 2026

ABBV ABT ADM ADP AFL ALB AMCR

Dec 30, 2025, 1:31 PM EST - 2 days ago

The Big 3: JNJ, SNDK, TWLO

TWLO SNDK

Dec 30, 2025, 9:55 AM EST - 2 days ago

Jim Cramer Says ‘The Year of Magical Investing' Is Over—Here's What To Do Now

Dec 30, 2025, 5:05 AM EST - 2 days ago

More Upside For JNJ Stock In 2026?

Dec 29, 2025, 1:56 PM EST - 3 days ago

Dogs of the Dow Had a Strong Year as Dividends Paid Off

HD IBM NKE UNH

Dec 29, 2025, 8:00 AM EST - 3 days ago

Johnson & Johnson completes acquisition of Halda Therapeutics and its novel platform to revolutionize cancer treatment and enable next-generation oral therapies

Dec 28, 2025, 6:44 AM EST - 4 days ago

Best Dividend Kings: December 2025

ABBV ABM ABT ADM ADP AWR BDX

Dec 26, 2025, 8:13 AM EST - 6 days ago

Johnson & Johnson halts mid-stage trial of experimental eczema drug

Dec 23, 2025, 11:41 AM EST - 9 days ago

J&J ordered to pay record $1.5B in talc cancer lawsuit — while vowing to appeal ‘unconstitutional' ruling

Dec 23, 2025, 12:34 AM EST - 9 days ago

J&J vows appeal after US jury hits it with record $1.5 billion talc cancer award

Dec 22, 2025, 11:15 PM EST - 9 days ago

Over $1.5 Billion Baltimore Verdict Holds Johnson & Johnson Liable Over Iconic Baby Powder

Dec 20, 2025, 3:55 AM EST - 12 days ago

Minnesota jury says Johnson & Johnson owes $65.5 million to woman with cancer who used talcum powder

Dec 19, 2025, 5:54 PM EST - 13 days ago

Minnesota Jury Delivers $65.5 Million History-Making Verdict Against Johnson & Johnson

Dec 18, 2025, 8:00 AM EST - 14 days ago

Johnson & Johnson Receives FDA Approval for TRUFILL n‑BCA Liquid Embolic System for the Treatment of Symptomatic Chronic Subdural Hematoma

Dec 18, 2025, 2:09 AM EST - 14 days ago

Johnson & Johnson: Valuation Premium Justified By Accelerating Growth And Mix Premiumization

Dec 17, 2025, 6:49 PM EST - 15 days ago

U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Enables the Simplest, Shortest Administration Time for a First-Line Combination Regimen when Combined with LAZCLUZE® (lazertinib)

Dec 15, 2025, 6:22 PM EST - 17 days ago

Final Trade: JNJ, NVO, UBER, BMY

BMY NVO UBER

Dec 15, 2025, 4:27 PM EST - 17 days ago

Johnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results

Dec 15, 2025, 10:39 AM EST - 17 days ago

US FDA grants priority voucher to J&J's blood cancer treatment

Dec 14, 2025, 9:00 AM EST - 18 days ago

California Jury Awards $40 Million in Landmark Talc Verdict Against Johnson & Johnson

Dec 12, 2025, 9:08 PM EST - 19 days ago

Jury orders Johnson & Johnson to pay $40 million to two women in latest talc trial

Dec 12, 2025, 8:25 PM EST - 19 days ago

U.S. FDA approves AKEEGA® as the first precision therapy for BRCA2-mutated metastatic castration-sensitive prostate cancer with 54% reduction in disease progression vs standard of care*

Dec 11, 2025, 7:05 PM EST - 21 days ago

Johnson & Johnson: Reliable Cash Flows, Moderate Expectations

Dec 9, 2025, 9:50 PM EST - 22 days ago

GS Equity Income Fund: Q3 2025 Witnesses Fundamental Strength And Expansive Margin Opportunities

ACN DHI HON KVUE ORCL SSB WFC

Dec 9, 2025, 12:18 PM EST - 23 days ago

5 defensive stocks traders are buying before the Fed rate-cut decision

DUK KO NEE PG

$Unprecedented results from the Phase 3 MajesTEC-3 study support TECVAYLI® plus DARZALEX FASPRO® as a potential standard of care as early as second line for patients with relapsed/refractory multiple myeloma$

Dec 9, 2025, 7:44 AM EST - 23 days ago

Unprecedented results from the Phase 3 MajesTEC-3 study support TECVAYLI® plus DARZALEX FASPRO® as a potential standard of care as early as second line for patients with relapsed/refractory multiple myeloma

Dec 8, 2025, 4:25 PM EST - 24 days ago

Johnson & Johnson to Participate in the 44th Annual J.P. Morgan Healthcare Conference

$Earlier use of CARVYKTI® demonstrated lasting treatment-free remissions at 2.5 years in patients with relapsed or refractory multiple myeloma$

Dec 6, 2025, 9:30 AM EST - 26 days ago

Earlier use of CARVYKTI® demonstrated lasting treatment-free remissions at 2.5 years in patients with relapsed or refractory multiple myeloma

Dec 5, 2025, 4:20 PM EST - 27 days ago

Johnson & Johnson's INLEXZO™ (gemcitabine intravesical system) delivers 74 percent disease-free survival at one year in BCG-unresponsive, high-risk, papillary-only NMIBC

Dec 3, 2025, 2:13 PM EST - 4 weeks ago

Johnson & Johnson (JNJ) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Dec 1, 2025, 1:36 PM EST - 4 weeks ago

American Century Value Fund Q3 2025 Contributors/Detractors And Notable Trades

BWA CNC CRM KVUE LMT NVT TER

Dec 1, 2025, 1:23 PM EST - 4 weeks ago

16 Quality Stocks to Own for a Volatile Market

CSCO LLY XOM

Dec 1, 2025, 8:18 AM EST - 4 weeks ago

Johnson & Johnson receives European Commission approval of IMAAVY® (nipocalimab), a new FcRn blocker offering sustained disease control in a broad population of people living with generalised myasthenia gravis (gMG)

Nov 29, 2025, 8:02 AM EST - 4 weeks ago

Best Dividend Aristocrats For December 2025

ABBV ABT ADM ADP AFL ALB AMCR

Nov 29, 2025, 1:45 AM EST - 4 weeks ago

Dogs Of The Dow Continue Outperforming Broader Market

AMGN DIA MAGS SPY

Nov 28, 2025, 7:50 AM EST - 4 weeks ago

Wasatch Global Value Fund Q3 2025 Performance Review

BABA CNC DOX NVDA

Nov 25, 2025, 5:20 AM EST - 5 weeks ago

JNJ Stock vs. PFE Stock: Which Pharmaceutical Giant Is A Better Buy?

PFE

Nov 18, 2025, 4:21 PM EST - 6 weeks ago

Why biotech and drug stocks are on the mend even though the rest of the market is hurting

AZN LLY MDT MRK NVO OLMA PFE

Nov 18, 2025, 8:25 AM EST - 6 weeks ago

Global drugmakers rush to boost US presence as tariff threat looms

ABBV AMGN AZN BIIB GILD GSK LLY

Nov 17, 2025, 6:07 PM EST - 6 weeks ago

Vida Ventures Marks Fourth Major Portfolio Acquisition in 2025, Capping a Record-Setting Year for Its Science-Led, Discipline-Driven Strategy

Nov 17, 2025, 1:17 PM EST - 6 weeks ago

Johnson & Johnson (JNJ) Presents at 7th Annual Wolfe Research Healthcare Conference Transcript

Nov 17, 2025, 8:29 AM EST - 6 weeks ago

Johnson & Johnson to Buy Halda Therapeutics For $3.05 Billion

Nov 17, 2025, 8:15 AM EST - 6 weeks ago

Halda Therapeutics Announces Acquisition by Johnson & Johnson

Nov 17, 2025, 8:07 AM EST - 6 weeks ago

J&J to buy cancer therapy developer Halda Therapeutics for $3.05 billion

Nov 17, 2025, 8:05 AM EST - 6 weeks ago

New long-term data reinforces TREMFYA® (guselkumab) as the only IL-23 inhibitor proven to substantially inhibit structural joint damage in active psoriatic arthritis

Nov 17, 2025, 8:00 AM EST - 6 weeks ago

Johnson & Johnson Set to Revolutionize the Treatment of Cancer With the Acquisition of Halda Therapeutics

Nov 14, 2025, 3:19 PM EST - 6 weeks ago

Biopharma companies have confidence in their ability to do deals: BMO's Evan Seigerman

ABBV AZN LLY MRK NVO PFE XLV

Nov 14, 2025, 8:03 AM EST - 6 weeks ago

Bristol Myers, J&J halt heart drug trial after interim review

BMY

Nov 11, 2025, 1:41 PM EST - 7 weeks ago

Johnson & Johnson (JNJ) Presents at UBS Global Healthcare Conference 2025 Transcript

Nov 11, 2025, 12:51 PM EST - 7 weeks ago

Johnson & Johnson (JNJ) Presents at Guggenheim Securities 2nd Annual Healthcare Innovation Conference Transcript

TalkMarkets Jan. 1 at 3:00 PM

Johnson & Johnson Near Year High $JNJ Also $ABBV $BSX $HALO https://talkmarkets.com/content/stocks--equities/johnson--johnson-near-year-high?post=547778&userid=166882

0 · Reply

SueHarri Jan. 1 at 2:15 PM

$CVKD Cadrenal’s strategic pipeline build could reshape how investors see the company: https://finance.yahoo.com/news/cadrenals-quiet-expansion-play-starting-160000079.html $ASTS $NOW $JNJ $ASML

0 · Reply

LeeBeckwith675 Jan. 1 at 1:34 PM

$MA $XOM $JNJ $PLTR $NFLX I agree with this

0 · Reply

MoneyGroupLLC Jan. 1 at 12:04 AM

0 · Reply

Jamessmithy Dec. 31 at 11:17 PM

$JNJ $CL $LEU $PG $CRSP

0 · Reply

Night_Owl_Biotech Dec. 31 at 9:56 PM

1 · Reply

N0Bounds Dec. 31 at 9:49 PM

SNSE is the Next big Retail Squeeze!! $JNJ $OCG $SES $UAMY $JOBY /

0 · Reply

N0Bounds Dec. 31 at 9:24 PM

$GEMI $LI $JNJ $UAMY $NDAQ bw

0 · Reply

DennisFrank550 Dec. 31 at 4:49 PM

$MA $XOM $JNJ $PLTR $NFLX I agree with this

0 · Reply

Investor203 Dec. 31 at 3:04 PM

0 · Reply

Investor203 Dec. 31 at 2:44 PM

$VNDA $JNJ or $LLY will buy at $30-$40

0 · Reply

Investor203 Dec. 31 at 12:11 AM

$VNDA is $JNJ buying VNDA?

0 · Reply

am2 Dec. 30 at 5:48 PM

$RNXT Most unexpected price action today. Let us hope there is some validity to the possible interest of $JNJ in $RNXT.

2 · Reply

1986iamwallstreet Dec. 30 at 2:46 PM

$ABVX already know they have multiple bidders I believe $JNJ is one of them 🚀🚀🚀🚀

2 · Reply

EthelBurkhardt272 Dec. 30 at 2:00 PM

$JNJ Defensive flow coming back institutions like this level

0 · Reply

EliteStockTrader Dec. 30 at 12:56 PM

$JNJ Current Price & Change: $207.56 (-0.03%) Trend Indicator: Bullish RSI Level: 59.8 Volume Activity: -48.3% vs avg Volatility: 1.21% Price Target: $213.04 Confidence: 84% I do not provide personalized financial advice or sell premium subscriptions. Any communication requesting payment for services is unauthorized. My only official outlet is https://stocksecret.news Always conduct your own due diligence.

0 · Reply

TraderDaKing Dec. 30 at 12:12 PM

$ELTP $PFE $JNJ $LIY.X This is the 2nd to last day... Make it a good one.

0 · Reply

EliteStockTrader Dec. 30 at 6:11 AM

$JNJ Current Price & Change: $207.56 (-0.03%) Trend Indicator: Bullish RSI Level: 59.8 Volume Activity: -48.3% vs avg Volatility: 1.21% Price Target: $211.77 Confidence: 89%

0 · Reply

topstockalerts Dec. 29 at 8:58 PM

The Dogs of the Dow delivered a strong performance in 2025, gaining an average of 17.8% through late December and outperforming the broader Dow’s 14.5% rise. High-yield dividend payers led the way, with healthcare names and legacy tech stocks posting gains of roughly 28% to 44%, marking the group’s best equal-weighted year since 2019. Dividend stocks could continue to shine in 2026 if falling interest rates and lower bond yields push income-focused investors toward equities. As stock prices rose in 2025, some current Dogs are likely to drop off next year due to lower dividend yields, while underperformers such as Nike, UnitedHealth, and Home Depot may enter the group. Analysts expect a rebound for these potential new Dogs, with consensus price targets implying meaningful upside. Meanwhile, several high-yield names are expected to remain, with telecom and energy stocks standing out for their attractive yields and relatively low valuations. $DJIA $JNJ $IBM $NKE $HD

0 · Reply

Quantumup Dec. 29 at 7:56 PM

BTIG reiterated $APGE Buy/$115 $JNJ $REGN - $SNY $NKTR KYMR CLDX ACRS CRVS AZN AMGN BTIG said in its note to investors: JNJ's (Not Rated) DUPLEX-AD trial was the only other clinical-stage effort we are aware of that was comparing a novel construct (JNJ-5939, bispecific mAb targeting IL-4Ralpha and IL-31; acquired for $1.25B in 2024) directly to Dupixent (SNY, REGN; both Not Rated) in atopic dermatitis. We view this update as a positive clearing event for APG279 (co-formulated anti-IL-13 and anti-OX40L; a more compelling combo, in our opinion) and potentially APG777 as well, considering APEX Part A generated the highest EASI-75 watermark we have seen from any biologic along with the opportunity for even greater efficacy in APEX Part B results expected in 2Q26 (discussed below). Initial APG279 head-to-head results vs. Dupixent are expected in 2H26 where we could see JAK-like efficacy supported by APG279's thoughtfully nonoverlapping (and much safer) MOAs.

0 · Reply

MoneyGroupLLC Dec. 29 at 5:33 PM

Enter: $JNJ Calls Strike Price: $210 Expiry Date: JAN 23 2026 Buy in Price: $3.85 - $4.15 Sell Price: $8.78 Profit : +128% (Turn every $1 into $2.28) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

prismmarketview Dec. 29 at 3:17 PM

Johnson & Johnson (NYSE: $JNJ) has closed its $3.05 billion all‑cash acquisition of Halda Therapeutics, adding HLD‑0915—a once‑daily oral RIPTAC small‑molecule for metastatic castration‑resistant prostate cancer. https://prismmarketview.com/johnson-johnson-completes-acquisition-of-halda-therapeutics-expanding-next-generation-oncology-platform/

0 · Reply

Market Cap	498.51B
Revenue (ttm)	88.82B
Net Income (ttm)	14.07B
EPS (ttm)	N/A
PE Ratio	20.00
Forward PE	19.10
Profit Margin	15.84%
Debt to Equity Ratio	0.50

Volume	4,084,000
Avg Vol	8,426,506
Day's Range	N/A - N/A
Shares Out	2.41B
Stochastic %K	47%
Beta	0.36
Analysts	Strong Sell
Price Target	$211.12